查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
克隆和誘變市場規模,份額和趨勢分析報告:按產品(克隆試劑盒,誘變試劑盒),按技術(Topo PCR克隆,平端克隆),按最終用途,按地區,分部預測,2023-2030年
市場調查報告書
商品編碼
1178548

克隆和誘變市場規模,份額和趨勢分析報告:按產品(克隆試劑盒,誘變試劑盒),按技術(Topo PCR克隆,平端克隆),按最終用途,按地區,分部預測,2023-2030年

Cloning And Mutagenesis Market Size, Share & Trends Analysis Report By Product (Cloning Kits, Mutagenesis Kits), By Technology (Topo PCR Cloning, Blunt End Cloning), By End-user, By Region, And Segment Forecasts, 2023 - 2030
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

克隆和誘變市場的增長和趨勢

Grand View Research, Inc. 的一份新報告預測，2023 年至 2030 年全球克隆和誘變市場將以 18.97% 的複合年增長率增長，到 2030 年將達到 94.4 億美元。對用於藥物開發的蛋白質工程的日益關注以及對基因工程產品不斷增長的需求是推動市場的主要因素。此外，遺傳病和慢性病的增加增加了對個性化醫療的需求。

克隆和誘變是藥物開發中蛋白質工程中使用的基本技術。這些技術幫助研究人員通過核甘酸插入、刪除和替換來改變蛋白質序列，以開發治療性蛋白質。此外，克隆和誘變可以幫助開發更有效、更安全、成本更低且更容易獲得的藥物。例如，目前有超過200種多□和蛋白質藥物獲得FDA批准。因此，這些技術在蛋白質工程中的應用可能會在預測期內推動市場增長。

預計 COVID-19 大流行將對市場增長產生積極影響。克隆和誘變技術已被用於克隆 SARS-CoV-2 基因組。例如，在 2020 年 5 月發表在《Nature》雜誌上的一篇論文中，研究人員使用基於酵母的方法克隆了 SARC-CoV-2 基因組。基因組修飾和重建對於研究感染和復制方法以及可能對病毒起作用的藥物和疫苗至關重要。因此，COVID-19 相關研究有望提高這些技術的利用率，從而推動預測期內的市場增長。

遺傳病和慢性病的日益流行增加了對個性化醫療的需求。克隆和誘變技術用於研究個體的特定疾病，以幫助診斷、規劃治療和確認治療效果。此外，增加對個性化醫療的資助有望在研究期間促進克隆和誘變的應用。例如，2022 年 2 月，VariantyxS 獲得了價值 4150 萬美元的資金，用於推出一種新的精準腫瘤學解決方案。

此外，在合成生物學中越來越多地使用克隆和誘變工具推動了市場增長。合成生物學使用克隆和誘變來幫助微調藥物，方法是改善現有藥物的治療特性並最大限度地減少或消除對個體的副作用。合成基因為專門的腫瘤學組織開闢了道路，可以開發針對患者腫瘤特定 DNA 序列的個性化癌症疫苗。幾種這樣的個性化癌症疫苗正處於臨床階段。還有幾種基於基因的疫苗正在開發中以對抗 COVID-19，但需要克隆和誘變技術來生產具有成本效益和高效的疫苗。預計此類應用將在研究期間推動市場增長。

另一方面，高昂的維護成本、合格研究人員的有限生存能力以及與克隆和誘變生成工具相關的高培訓要求可能會在一定程度上限制市場增長。然而，主要參與者正在不斷努力開發具有成本效益的設備，並提供一些實踐培訓計劃來克服限制，這有望推動市場增長。可能會創造前景。

克隆和誘變市場報告要點

按產品劃分，克隆試劑盒部分在 2022 年佔據了最大份額。這是由於這些試劑盒的廣泛應用，包括生物製藥、基因治療和基因分析。

從技術上看，TOPO PCR 克隆部分在 2022 年佔據了最大份額。這是由於與連接、無限克隆和簡單引物設計等技術相關的優勢。

按最終用途劃分，生物製藥和製藥公司在 2022 年佔據最大份額，原因是克隆和誘變技術廣泛用於藥物發現和藥物開發。

由於政府投資舉措的增加、癌症等慢性病發病率的增加以及對生物技術技術的高需求，北美將在 2022 年主導全球市場

由於政府增加研發投資、對新療法的需求增加以及經濟改善，預計亞太地區未來將出現顯著增長。

目錄

第一章研究方法論

  • 市場細分和範圍
  • 調查方法
  • 信息採購
    • 購買的數據庫
    • GVR 內部數據庫
    • 次要信息
    • 初步調查
    • 初步調查詳情
  • 信息或數據分析
    • 數據分析模型
  • 市場製定和驗證
  • 型號詳情
    • 商品流向分析
      • 方法一：商品流動方法
      • 方法 2：使用自下而上的方法進行國別市場估算
  • 全球市場：複合年增長率計算
  • 調查假設
  • 二級信息列表
  • 主要信息列表
  • 目的
  • 縮略語表

第二章市場定義

第三章執行摘要

  • 市場概況

4. 全球克隆和誘變市場變量、趨勢和範圍

  • 克隆和誘變市場譜系展望
    • 母公司市場展望
  • 繪製滲透率和增長前景
  • 監管框架
  • 市場驅動力分析
    • 對個性化醫療的需求不斷增長
    • 對蛋白質工程的興趣日益濃厚
    • 對轉基因產品的需求不斷增長
  • 市場約束因素分析
    • 與克隆和誘變工具和設備相關的高維護成本
    • 合格研究人員的可用性有限，需要進行有關克隆和誘變過程的高級培訓
  • 市場機會分析
    • 增加克隆和誘變在合成生物學中的應用
  • 波特五力分析
  • 克隆誘變市場：COVID-19 的影響分析

5. 克隆和誘變市場：細分分析，按產品，2018-2030 年（百萬美元）

  • 全球克隆和誘變市場：產品變異分析
  • 克隆試劑盒
  • 誘變試劑盒
  • 其他

6. 克隆和誘變市場：細分分析，按技術，2018-2030 年（百萬美元）

  • 全球克隆和誘變市場：技術波動分析
  • 拓撲聚合□鏈反應克隆
  • 平端克隆
  • 無縫克隆
  • 定點誘變
  • 其他

7. 克隆和誘變市場：細分分析，按最終用途，2018-2030 年（百萬美元）

  • 克隆和誘變市場：最終用戶變異分析
  • 生物製藥和製藥公司
  • CRO 和 CMO
  • 學術/研究機構

8. 克隆和誘變市場：-2018-2030 年按地區細分分析（百萬美元）

  • 克隆和誘變市場：區域差異分析
  • 北美
    • SWOT分析
    • 美國
      • 主要國家動態
      • 目標疾病的患病率
      • 競爭情景
      • 監管框架
      • 贖回場景
    • 加拿大
      • 主要國家動態
      • 目標疾病的患病率
      • 競爭情景
      • 監管框架
      • 贖回場景
  • 歐洲
    • SWOT分析
    • 德國
      • 主要國家動態
      • 目標疾病的患病率
      • 競爭情景
      • 監管框架
      • 贖回場景
    • 英國
      • 主要國家動態
      • 目標疾病的患病率
      • 競爭情景
      • 監管框架
      • 贖回場景
    • 法國
      • 主要國家動態
      • 目標疾病的患病率
      • 競爭情景
      • 監管框架
      • 贖回場景
    • 意大利
      • 主要國家動態
      • 目標疾病的患病率
      • 競爭情景
      • 監管框架
      • 贖回場景
    • 西班牙
      • 主要國家動態
      • 目標疾病的患病率
      • 競爭情景
      • 監管框架
      • 贖回場景
    • 丹麥
      • 主要國家動態
      • 目標疾病的患病率
      • 競爭情景
      • 監管框架
      • 贖回場景
    • 瑞典
      • 主要國家動態
      • 目標疾病的患病率
      • 競爭情景
      • 監管框架
      • 贖回場景
    • 挪威
      • 主要國家動態
      • 目標疾病的患病率
      • 競爭情景
      • 監管框架
      • 贖回場景
  • 亞太地區
    • SWOT分析
    • 日本
      • 主要國家動態
      • 目標疾病的患病率
      • 競爭情景
      • 監管框架
      • 贖回場景
    • 中國
      • 主要國家動態
      • 目標疾病的患病率
      • 競爭情景
      • 監管框架
      • 贖回場景
    • 印度
      • 主要國家動態
      • 目標疾病的患病率
      • 競爭情景
      • 監管框架
      • 贖回場景
    • 韓國
      • 主要國家動態
      • 目標疾病的患病率
      • 競爭情景
      • 監管框架
      • 贖回場景
    • 澳大利亞
      • 主要國家動態
      • 目標疾病的患病率
      • 競爭情景
      • 監管框架
      • 贖回場景
    • 泰國
      • 主要國家動態
      • 目標疾病的患病率
      • 競爭情景
      • 監管框架
      • 贖回場景
  • 拉丁美洲
    • SWOT分析
    • 巴西
      • 主要國家動態
      • 目標疾病的患病率
      • 競爭情景
      • 監管框架
      • 贖回場景
    • 墨西哥
      • 主要國家動態
      • 目標疾病的患病率
      • 競爭情景
      • 監管框架
      • 贖回場景
    • 阿根廷
      • 主要國家動態
      • 目標疾病的患病率
      • 競爭情景
      • 監管框架
      • 贖回場景
  • 多邊環境協定
    • SWOT分析
    • 南非
      • 主要國家動態
      • 目標疾病的患病率
      • 競爭情景
      • 監管框架
      • 贖回場景
    • 沙特阿拉伯
      • 主要國家動態
      • 目標疾病的患病率
      • 競爭情景
      • 監管框架
      • 贖回場景
    • 阿拉伯聯合酋長國
      • 主要國家動態
      • 目標疾病的患病率
      • 競爭情景
      • 監管框架
      • 贖回場景
    • 科威特
      • 主要國家動態
      • 目標疾病的患病率
      • 競爭情景
      • 監管框架
      • 贖回場景

第九章競爭格局

  • 參會概況
    • Agilent Technologies, Inc.
    • Takara Bio Co., Ltd.
    • Thermo Fisher Scientific
    • new england bio lab
    • Merck KGaA
    • Promega Corporation
    • Bio-Rad Laboratories, Inc.
    • Danaher
    • Jena Bioscience GmbH
    • assay jenny
    • Trans Gen Biotech Co., Ltd.
  • 財務績效
  • 進入公司
    • 市場領導者
      • 2022 年克隆和誘變市場份額分析
    • 戰略規劃
      • 擴張
      • 獲得
      • 合作
      • 產品/服務發布
      • 合夥
      • 其他
Product Code: GVR-4-68040-010-3

Cloning And Mutagenesis Market Growth & Trends:

The global cloning and mutagenesis market size is expected to reach USD 9.44 billion by 2030, according to a new report by Grand View Research, Inc., expanding at a CAGR of 18.97% from 2023 to 2030. Growing focus on protein engineering for drug development and increasing demand for genetically modified products are major factors driving the market. In addition, the rising prevalence of genetic disorders and chronic diseases is increasing the demand for personalized medicine.

Cloning and mutagenesis are the basic methodologies employed in protein engineering during drug development. These techniques help researchers in the modification of protein sequences through insertion, deletion, or substitution of nucleotides to develop therapeutic proteins. In addition, cloning and mutagenesis aid in the development of more efficient and safer drugs, which can be readily available at a lower cost. For instance, currently, there are more than 200 peptide and protein drugs approved by the FDA. Hence, applications of these techniques in protein engineering are likely to fuel market growth over the forecast years.

The COVID-19 pandemic is expected to positively influence market growth. Cloning and mutagenesis techniques are used to clone the SARS-CoV-2 genome. For instance, according to an article published in Nature in May 2020, researchers have constructed a clone of the SARC-CoV-2 genome by using yeast-based method. Modifying or reconstructing genomes is essential for studying methods of infection, replication, and potential drugs and vaccines that might work against the virus. As a result, the usage of these techniques has increased due to COVID-19-related research, which is expected to fuel the market growth during the forecast period.

The growing prevalence of genetic disorders and chronic diseases is increasing the demand for personalized medicine. Cloning and mutagenesis techniques are used in studying a particular disease of an individual to aid diagnosis, develop a treatment plan, and identify the treatment effect. Moreover, increasing funding for personalized medicine is anticipated to boost the applications of cloning and mutagenesis during the study period. For instance, in February 2022, VariantyxS secured funding worth USD 41.5 million to launch novel solutions in precision oncology.

Furthermore, increasing applications of cloning and mutagenesis tools in synthetic biology are accelerating market growth. Synthetic biology is aiding in fine-tuning of already available drugs by using cloning and mutagenesis to improve their therapeutic attributes and produce minimal or no side effects for individuals. Synthetic genes created the way for oncology-focused organizations to develop personalized cancer vaccines to the specific DNA sequence of a patient's tumor. Several such personalized cancer vaccines are in the clinical phase. There are several gene-based vaccines that are also in development to fight COVID-19, which require cloning and mutagenesis techniques to produce cost-effective and efficient vaccines. Such applications are expected to fuel the market growth during the study period.

On the other hand, high maintenance cost associated with cloning and mutagenesis tools, limited viability of qualified researchers. and the need for advanced training may limit the market growth to a certain extent. However, key players are continuously striving to develop cost-effective instruments and offering several hands-on training programs to overcome the limitations, which is likely to create growth prospects for the market.

Cloning And Mutagenesis Market Report Highlights:

  • By product, the cloning kits segment held the largest share in 2022. This is attributed to the broad range of applications of these kits in biopharmaceuticals, gene therapy, and gene analysis among others
  • By technology, the TOPO PCR cloning segment held the largest share in 2022 due to the advantages associated with the technology such as ligation and restriction-free cloning and simple design of primers
  • By end-user, the biopharmaceutical and pharmaceutical companies segment held the largest share in 2022 owing to the widespread use of cloning and mutagenesis in biopharmaceuticals for drug discovery and development
  • North America dominated the global market in 2022 due to a rise in investment initiatives by the government, increasing incidence of chronic diseases such as cancer, and high demand for biotechnology techniques
  • Asia Pacific is expected to grow considerably in the future owing to the increasing R&D investment by governments, rising demand for novel therapeutics, and improving economy

Table of Contents

Chapter 1 Research Methodology

  • 1.1 Market Segmentation & Scope
    • 1.1.1 Estimates And Forecast Timeline
  • 1.2 Research Methodology
  • 1.3 Information Procurement
    • 1.3.1 Purchased Database
    • 1.3.2 GVR's Internal Database
    • 1.3.3 Secondary Sources
    • 1.3.4 Primary Research
    • 1.3.5 Details Of Primary Research
  • 1.4 Information or Data Analysis
    • 1.4.1 Data Analysis Models
  • 1.5 Market Formulation & Validation
  • 1.6 Model Details
    • 1.6.1 Commodity Flow Analysis
      • 1.6.1.1 Approach 1: Commodity flow approach
      • 1.6.1.2 Approach 2: Country-wise market estimation using bottom-up approach
  • 1.7 Global Market: CAGR Calculation
  • 1.8 Research Assumptions
  • 1.9 List of Secondary Sources
  • 1.10 List of Primary Sources
  • 1.11 Objectives
    • 1.11.1 Objective 1:
    • 1.11.2 Objective 2:
  • 1.12 List of Abbreviations

Chapter 2 Market Definitions

Chapter 3 Executive Summary

  • 3.1 Market Summary

Chapter 4 Global Cloning and Mutagenesis Market Variables, Trends, & Scope

  • 4.1 Cloning and Mutagenesis Market Lineage Outlook
    • 4.1.1 Parent market outlook
  • 4.2 Penetration and Growth Prospect Mapping
  • 4.3 Regulatory Framework
  • 4.4 Market Driver Analysis
    • 4.4.1 Increasing demand for personalized medicine
    • 4.4.2 Growing focus on protein engineering
    • 4.4.3 Rising demand for genetically modified products
  • 4.5 Market Restraint Analysis
    • 4.5.1 High maintanance cost associated with cloning and mutagenesis tools & instruments
    • 4.5.2 Limited aviability of qualified researchers and need for advanced training in cloning and mutagenesis processes
  • 4.6 Market Opportunity Analysis
    • 4.6.1 Increasing applications of cloning and mutagenesis in synthetic biology
  • 4.7 Porter's Five Forces Analysis
  • 4.8 Cloning and Mutagenesis Market: Covid-19 Impact Analysis

Chapter 5 Cloning and Mutagenesis Market - Segment Analysis, by product, 2018 - 2030 (USD Million)

  • 5.1 Global Cloning and Mutagenesis Market: Product Movement Analysis
  • 5.2 Cloning Kits
    • 5.2.1 Cloning kits market estimates and forecast, 2018 - 2030 (USD Million)
  • 5.3 Mutagenesis Kits
    • 5.3.1 Mutagenesis kits market estimates and forecast, 2018 - 2030 (USD Million)
  • 5.4 Others
    • 5.4.1 Others market estimates and forecast, 2018 - 2030 (USD Million)

Chapter 6 Cloning and Mutagenesis Market - Segment Analysis, by Technology, 2018 - 2030 (USD Million)

  • 6.1 Global Cloning and Mutagenesis Market: Technology Movement Analysis
  • 6.2 Topo PCR Cloning
    • 6.2.1 Topo PCR cloning market estimates and forecast, 2018 - 2030 (USD Million)
  • 6.3 Blunt End Cloning
      • 6.3.1Blunt end cloning market estimates and forecast, 2018 - 2030 (USD Million)
  • 6.4 Seamless Cloning
    • 6.4.1 Seamless cloning market estimates and forecast, 2018 - 2030 (USD Million)
  • 6.5 Site-Directed Mutagenesis
    • 6.5.1 Site-directed mutagenesis market estimates and forecast, 2018 - 2030 (USD Million)
  • 6.6 Others
    • 6.6.1 Others market estimates and forecast, 2018 - 2030 (USD Million)

Chapter 7 Cloning and Mutagenesis Market - Segment Analysis, by End-user, 2018 - 2030 (USD Million)

  • 7.1 Cloning and Mutagenesis Market: End-user Movement Analysis
  • 7.2 Biopharmaceutical & Pharmaceutical Companies
    • 7.2.1 Biopharmaceutical & pharmaceutical companies market estimates and forecast, 2018 - 2030 (USD Million)
  • 7.3 CROs & CMOs
    • 7.3.1 CROs & CMOs market estimates and forecast, 2018 - 2030 (USD Million)
  • 7.4. Academic & Research Institutes
    • 7.4.1 Academic & research institutes market estimates and forecast, 2018 - 2030 (USD Million)

Chapter 8 Cloning and Mutagenesis Market: - Segment Analysis, by Region, 2018 - 2030 (USD Million)

  • 8.1 Cloning and Mutagenesis Market: Regional Movement Analysis
  • 8.2 North America
    • 8.2.1 SWOT Analysis
      • 8.2.1.1 North America cloning and mutagenesis market, by product, 2018 - 2030 (USD Million)
      • 8.2.1.2 North America cloning and mutagenesis market, by technology, 2018 - 2030 (USD Million)
      • 8.2.1.3 North America cloning and mutagenesis market, by end-user, 2018 - 2030 (USD Million)
    • 8.2.2 U.S.
      • 8.2.2.1 Key Country Dynamics
      • 8.2.2.2 Target Disease Prevalence
      • 8.2.2.3 Competitive Scenario
      • 8.2.2.4 Regulatory Framework
      • 8.2.2.5 Reimbursement Scenario
      • 8.2.2.6 U.S. cloning and mutagenesis market, by product, 2018 - 2030 (USD Million)
      • 8.2.2.7 U.S. cloning and mutagenesis market, by technology, 2018 - 2030 (USD Million)
      • 8.2.2.8 U.S. cloning and mutagenesis market, by end-user, 2018 - 2030 (USD Million)
    • 8.2.3 Canada
      • 8.2.3.1 Key Country Dynamics
      • 8.2.3.2 Target Disease Prevalence
      • 8.2.3.3 Competitive Scenario
      • 8.2.3.4 Regulatory Framework
      • 8.2.3.5 Reimbursement Scenario
      • 8.2.3.6 Canada cloning and mutagenesis market, by product, 2018 - 2030 (USD Million)
      • 8.2.3.7 Canada cloning and mutagenesis market, by technology, 2018 - 2030 (USD Million)
      • 8.2.3.8 Canada cloning and mutagenesis market, by end-user, 2018 - 2030 (USD Million)
  • 8.3 Europe
    • 8.3.1 SWOT Analysis
      • 8.3.1.1 Europe cloning and mutagenesis market, by product, 2018 - 2030 (USD Million)
      • 8.3.1.2 Europe cloning and mutagenesis market, by technology, 2018 - 2030 (USD Million)
      • 8.3.1.4 Europe cloning and mutagenesis market, by end-user, 2018 - 2030 (USD Million)
    • 8.3.2 Germany
      • 8.3.2.1 Key Country Dynamics
      • 8.3.2.2 Target Disease Prevalence
      • 8.3.2.3 Competitive Scenario
      • 8.3.2.4 Regulatory Framework
      • 8.3.2.5 Reimbursement Scenario
      • 8.3.2.6 Germany cloning and mutagenesis market, by product, 2018 - 2030 (USD Million)
      • 8.3.2.7 Germany cloning and mutagenesis market, by technology, 2018 - 2030 (USD Million)
      • 8.3.2.8 Germany cloning and mutagenesis market, by end-user, 2018 - 2030 (USD Million)
    • 8.3.3 U.K.
      • 8.3.3.1 Key Country Dynamics
      • 8.3.3.2 Target Disease Prevalence
      • 8.3.3.3 Competitive Scenario
      • 8.3.3.4 Regulatory Framework
      • 8.3.3.5 Reimbursement Scenario
      • 8.3.3.6 U.K. cloning and mutagenesis market, by product, 2018 - 2030 (USD Million)
      • 8.3.3.7 U.K. cloning and mutagenesis market, by technology, 2018 - 2030 (USD Million)
      • 8.3.3.8 U.K. cloning and mutagenesis market, by end-user, 2018 - 2030 (USD Million)
    • 8.3.4 France
      • 8.3.4.1 Key Country Dynamics
      • 8.3.4.2 Target Disease Prevalence
      • 8.3.4.3 Competitive Scenario
      • 8.3.4.4 Regulatory Framework
      • 8.3.4.5 Reimbursement Scenario
      • 8.3.4.6 France cloning and mutagenesis market, by product, 2018 - 2030 (USD Million)
      • 8.3.4.7 France cloning and mutagenesis market, by technology, 2018 - 2030 (USD Million)
      • 8.3.4.8 France cloning and mutagenesis market, by end-user, 2018 - 2030 (USD Million)
    • 8.3.5 Italy
      • 8.3.5.1 Key Country Dynamics
      • 8.3.5.2 Target Disease Prevalence
      • 8.3.5.3 Competitive Scenario
      • 8.3.5.4 Regulatory Framework
      • 8.3.5.5 Reimbursement Scenario
      • 8.3.5.6 Italy cloning and mutagenesis market, by product, 2018 - 2030 (USD Million)
      • 8.3.5.7 Italy cloning and mutagenesis market, by technology, 2018 - 2030 (USD Million)
      • 8.3.5.8 Italy cloning and mutagenesis market, by end-user, 2018 - 2030 (USD Million)
    • 8.3.6 Spain
      • 8.3.6.1 Key Country Dynamics
      • 8.3.6.2 Target Disease Prevalence
      • 8.3.6.3 Competitive Scenario
      • 8.3.6.4 Regulatory Framework
      • 8.3.6.5 Reimbursement Scenario
      • 8.3.6.6 Spain cloning and mutagenesis market, by product, 2018 - 2030 (USD Million)
      • 8.3.6.7 Spain cloning and mutagenesis market, by technology, 2018 - 2030 (USD Million)
      • 8.3.6.8 Spain cloning and mutagenesis market, by end-user, 2018 - 2030 (USD Million)
    • 8.3.7 Denmark
      • 8.3.7.1 Key Country Dynamics
      • 8.3.7.2 Target Disease Prevalence
      • 8.3.7.3 Competitive Scenario
      • 8.3.7.4 Regulatory Framework
      • 8.3.7.5 Reimbursement Scenario
      • 8.3.7.6 Denmark cloning and mutagenesis market, by product, 2018 - 2030 (USD Million)
      • 8.3.7.7 Denmark cloning and mutagenesis market, by technology, 2018 - 2030 (USD Million)
      • 8.3.7.8 Denmark cloning and mutagenesis market, by end-user, 2018 - 2030 (USD Million)
    • 8.3.8 Sweden
      • 8.3.8.1 Key Country Dynamics
      • 8.3.8.2 Target Disease Prevalence
      • 8.3.8.3 Competitive Scenario
      • 8.3.8.4 Regulatory Framework
      • 8.3.8.5 Reimbursement Scenario
      • 8.3.8.6 Sweden cloning and mutagenesis market, by product, 2018 - 2030 (USD Million)
      • 8.3.8.7 Sweden cloning and mutagenesis market, by technology, 2018 - 2030 (USD Million)
      • 8.3.8.8 Sweden cloning and mutagenesis market, by end-user, 2018 - 2030 (USD Million)
    • 8.3.9 Norway
      • 8.3.9.1 Key Country Dynamics
      • 8.3.9.2 Target Disease Prevalence
      • 8.3.9.3 Competitive Scenario
      • 8.3.9.4 Regulatory Framework
      • 8.3.9.5 Reimbursement Scenario
      • 8.3.9.6 Norway cloning and mutagenesis market, by product, 2018 - 2030 (USD Million)
      • 8.3.9.7 Norway cloning and mutagenesis market, by technology, 2018 - 2030 (USD Million)
      • 8.3.9.8 Norway cloning and mutagenesis market, by end-user, 2018 - 2030 (USD Million)
  • 8.4 Asia Pacific
    • 8.4.1 SWOT Analysis
      • 8.4.1.1 Asia Pacific cloning and mutagenesis market, by product, 2018 - 2030 (USD Million)
      • 8.4.1.2 Asia Pacific cloning and mutagenesis market, by technology, 2018 - 2030 (USD Million)
      • 8.4.1.3 Asia Pacific cloning and mutagenesis market, by end-user, 2018 - 2030 (USD Million)
    • 8.4.2 Japan
      • 8.4.2.1 Key Country Dynamics
      • 8.4.2.2 Target Disease Prevalence
      • 8.4.2.3 Competitive Scenario
      • 8.4.2.4 Regulatory Framework
      • 8.4.2.5 Reimbursement Scenario
      • 8.4.2.6 Japan cloning and mutagenesis market, by product, 2018 - 2030 (USD Million)
      • 8.4.2.7 Japan cloning and mutagenesis market, by technology, 2018 - 2030 (USD Million)
      • 8.4.2.8 Japan cloning and mutagenesis market, by end-user, 2018 - 2030 (USD Million)
    • 8.4.3 China
      • 8.4.3.1 Key Country Dynamics
      • 8.4.3.2 Target Disease Prevalence
      • 8.4.3.3 Competitive Scenario
      • 8.4.3.4 Regulatory Framework
      • 8.4.3.5 Reimbursement Scenario
      • 8.4.3.6 China cloning and mutagenesis market, by product, 2018 - 2030 (USD Million)
      • 8.4.3.7 China cloning and mutagenesis market, by technology, 2018 - 2030 (USD Million)
      • 8.4.3.8 China cloning and mutagenesis market, by end-user, 2018 - 2030 (USD Million)
    • 8.4.4 India
      • 8.4.4.1 Key Country Dynamics
      • 8.4.4.2 Target Disease Prevalence
      • 8.4.4.3 Competitive Scenario
      • 8.4.4.4 Regulatory Framework
      • 8.4.4.5 Reimbursement Scenario
      • 8.4.4.6 India cloning and mutagenesis market, by product, 2018 - 2030 (USD Million)
      • 8.4.4.7 India cloning and mutagenesis market, by technology, 2018 - 2030 (USD Million)
      • 8.4.4.8 India cloning and mutagenesis market, by end-user, 2018 - 2030 (USD Million)
    • 8.4.5 South Korea
      • 8.4.5.1 Key Country Dynamics
      • 8.4.5.2 Target Disease Prevalence
      • 8.4.5.3 Competitive Scenario
      • 8.4.5.4 Regulatory Framework
      • 8.4.5.5 Reimbursement Scenario
      • 8.4.5.6 South Korea cloning and mutagenesis market, by product, 2018 - 2030 (USD Million)
      • 8.4.5.7 South Korea cloning and mutagenesis market, by technology, 2018 - 2030 (USD Million)
      • 8.4.5.8 South Korea cloning and mutagenesis market, by end-user, 2018 - 2030 (USD Million)
    • 8.4.6 Australia
      • 8.3.9.1 Key Country Dynamics
      • 8.4.6.2 Target Disease Prevalence
      • 8.4.6.3 Competitive Scenario
      • 8.4.6.4 Regulatory Framework
      • 8.4.6.5 Reimbursement Scenario
      • 8.4.6.6 Australia cloning and mutagenesis market, by product, 2018 - 2030 (USD Million)
      • 8.4.6.7 Australia cloning and mutagenesis market, by technology, 2018 - 2030 (USD Million)
      • 8.4.6.8 Australia cloning and mutagenesis market, by end-user, 2018 - 2030 (USD Million)
    • 8.4.7 Thailand
      • 8.4.7.1 Key Country Dynamics
      • 8.4.7.2 Target Disease Prevalence
      • 8.4.7.3 Competitive Scenario
      • 8.4.7.4 Regulatory Framework
      • 8.4.7.5 Reimbursement Scenario
      • 8.4.7.6 Thailand cloning and mutagenesis market, by product, 2018 - 2030 (USD Million)
      • 8.4.7.7 Thailand cloning and mutagenesis market, by technology, 2018 - 2030 (USD Million)
      • 8.4.7.8 Thailand cloning and mutagenesis market, by end-user, 2018 - 2030 (USD Million)
  • 8.5 Latin America
    • 8.5.1 SWOT Analysis
      • 8.5.1.1 Latin America cloning and mutagenesis market, by product, 2018 - 2030 (USD Million)
      • 8.5.1.2 Latin America cloning and mutagenesis market, by technology, 2018 - 2030 (USD Million)
      • 8.5.1.3 Latin America cloning and mutagenesis market, by end-user, 2018 - 2030 (USD Million)
    • 8.5.2 Brazil
      • 8.5.2.1 Key Country Dynamics
      • 8.5.2.2 Target Disease Prevalence
      • 8.5.2.3 Competitive Scenario
      • 8.5.2.4 Regulatory Framework
      • 8.5.2.5 Reimbursement Scenario
      • 8.5.2.6 Brazil cloning and mutagenesis market, by product, 2018 - 2030 (USD Million)
      • 8.5.2.7 Brazil cloning and mutagenesis market, by technology, 2018 - 2030 (USD Million)
      • 8.5.2.8 Brazil cloning and mutagenesis market, by end-user, 2018 - 2030 (USD Million)
    • 8.5.3 Mexico
      • 8.5.3.1 Key Country Dynamics
      • 8.5.3.2 Target Disease Prevalence
      • 8.5.3.3 Competitive Scenario
      • 8.5.3.4 Regulatory Framework
      • 8.5.3.5 Reimbursement Scenario
      • 8.5.3.6 Mexico cloning and mutagenesis market, by product, 2018 - 2030 (USD Million)
      • 8.5.3.7 Mexico cloning and mutagenesis market, by technology, 2018 - 2030 (USD Million)
      • 8.5.3.8 Mexico cloning and mutagenesis market, by end-user, 2018 - 2030 (USD Million)
    • 8.5.4 Argentina
      • 8.5.4.1 Key Country Dynamics
      • 8.5.4.2 Target Disease Prevalence
      • 8.5.4.3 Competitive Scenario
      • 8.5.4.4 Regulatory Framework
      • 8.5.4.5 Reimbursement Scenario
      • 8.5.4.6 Argentina cloning and mutagenesis market, by product, 2018 - 2030 (USD Million)
      • 8.5.4.7 Argentina cloning and mutagenesis market, by technology, 2018 - 2030 (USD Million)
      • 8.5.4.8 Argentina cloning and mutagenesis market, by end-user, 2018 - 2030 (USD Million)
  • 8.6 MEA
    • 8.6.1 SWOT Analysis
      • 8.6.1.1 MEA cloning and mutagenesis market, by product, 2018 - 2030 (USD Million)
      • 8.6.1.2 MEA cloning and mutagenesis market, by technology, 2018 - 2030 (USD Million)
      • 8.6.1.3 MEA cloning and mutagenesis market, by end-user, 2018 - 2030 (USD Million)
    • 8.6.2 South Africa
      • 8.6.4.1 Key Country Dynamics
      • 8.6.2.2 Target Disease Prevalence
      • 8.6.2.3 Competitive Scenario
      • 8.6.2.4 Regulatory Framework
      • 8.6.2.5 Reimbursement Scenario
      • 8.6.2.6 Argentina cloning and mutagenesis market, by product, 2018 - 2030 (USD Million)
      • 8.6.2.7 Argentina cloning and mutagenesis market, by technology, 2018 - 2030 (USD Million)
      • 8.6.2.8 Argentina cloning and mutagenesis market, by end-user, 2018 - 2030 (USD Million)
    • 8.6.3 Saudi Arabia
      • 8.6.3.1 Key Country Dynamics
      • 8.6.3.2 Target Disease Prevalence
      • 8.6.3.3 Competitive Scenario
      • 8.6.3.4 Regulatory Framework
      • 8.6.3.5 Reimbursement Scenario
      • 8.6.3.6 Saudi Arabia cloning and mutagenesis market, by product, 2018 - 2030 (USD Million)
      • 8.6.3.7 Saudi Arabia cloning and mutagenesis market, by technology, 2018 - 2030 (USD Million)
      • 8.6.3.8 Saudi Arabia cloning and mutagenesis market, by end-user, 2018 - 2030 (USD Million)
    • 8.6.4 UAE
      • 8.6.4.1 Key Country Dynamics
      • 8.6.4.2 Target Disease Prevalence
      • 8.6.4.3 Competitive Scenario
      • 8.6.4.4 Regulatory Framework
      • 8.6.4.5 Reimbursement Scenario
      • 8.6.4.6 UAE cloning and mutagenesis market, by product, 2018 - 2030 (USD Million)
      • 8.6.4.7 UAE cloning and mutagenesis market, by technology, 2018 - 2030 (USD Million)
      • 8.6.4.8 UAE cloning and mutagenesis market, by end-user, 2018 - 2030 (USD Million)
    • 8.6.5 Kuwait
      • 8.6.5.1 Key Country Dynamics
      • 8.6.5.2 Target Disease Prevalence
      • 8.6.5.3 Competitive Scenario
      • 8.6.5.4 Regulatory Framework
      • 8.6.5.5 Reimbursement Scenario
      • 8.6.5.6 Kuwait cloning and mutagenesis market, by product, 2018 - 2030 (USD Million)
      • 8.6.5.7 Kuwait cloning and mutagenesis market, by technology, 2018 - 2030 (USD Million)
      • 8.6.5.8 Kuwait cloning and mutagenesis market, by end-user, 2018 - 2030 (USD Million)

Chapter 9 Competitive Landscape

  • 9.1 Participant's overview
    • 9.1.1 Agilent Technologies, Inc.
    • 9.1.2 Takara Bio Inc.
    • 9.1.3 Thermo Fisher Scientific, Inc.
    • 9.1.4 New England Biolabs
    • 9.1.5 Merck KGaA
    • 9.1.6 Promega Corporation
    • 9.1.7 Bio-Rad Laboratories, Inc.
    • 9.1.8 Danaher
    • 9.1.9 Jena Bioscience GmbH
    • 9.1.10 Assay Genie
    • 9.1.11 TransGen Biotech Co., Ltd.
  • 9.2 Financial performance
  • 9.3 Participant categorization
    • 9.3.1 Market leaders
      • 9.3.1.1 Cloning & mutagenesis market share analysis, 2022
    • 9.3.2 Strategy mapping
      • 9.3.2.1 Expansion
      • 9.3.2.2 Acquisition
      • 9.3.2.3 Collaborations
      • 9.3.2.4 Product/service launch
      • 9.3.2.5 Partnerships
      • 9.3.2.6 Others

List of Tables

  • Table 1. List of Secondary Sources
  • Table 2. List of Abbreviations
  • Table 3. Global Cloning and Mutagenesis Market, by Product, 2018 - 2030 (USD Million)
  • Table 4. Global Cloning and Mutagenesis Market, by Technology, 2018 - 2030 (USD Million)
  • Table 5. Global Cloning and Mutagenesis Market, End-user, 2018 - 2030 (USD Million)
  • Table 6. Global Cloning and Mutagenesis Market, by Region, 2018 - 2030 (USD Million)
  • Table 7. North America Cloning and Mutagenesis Market, by Country, 2018 - 2030 (USD Million)
  • Table 8. North America Cloning and Mutagenesis Market, by Product, 2018 - 2030 (USD Million)
  • Table 9. North AmericaCloning and Mutagenesis Market, by Technology, 2018 - 2030 (USD Million)
  • Table 10. North America Cloning and Mutagenesis Market, End-user, 2018 - 2030 (USD Million)
  • Table 11. U.S. Cloning and Mutagenesis Market, by Product, 2018 - 2030 (USD Million)
  • Table 12. U.S. Cloning and Mutagenesis Market, by Technology, 2018 - 2030 (USD Million)
  • Table 13. U.S. Cloning and Mutagenesis Market, End-user, 2018 - 2030 (USD Million)
  • Table 14. Canada Cloning and Mutagenesis Market, by Product, 2018 - 2030 (USD Million)
  • Table 15. Canada Cloning and Mutagenesis Market, by Technology, 2018 - 2030 (USD Million)
  • Table 16. Canada Cloning and Mutagenesis Market, End-user, 2018 - 2030 (USD Million)
  • Table 17. Europe Cloning and Mutagenesis Market, by Country, 2018 - 2030 (USD Million)
  • Table 18. Europe Cloning and Mutagenesis Market, by Product, 2018 - 2030 (USD Million)
  • Table 19. EuropeCloning and Mutagenesis Market, by Technology, 2018 - 2030 (USD Million)
  • Table 20. Europe Cloning and Mutagenesis Market, End-user, 2018 - 2030 (USD Million)
  • Table 21. U.K. Cloning and Mutagenesis Market, by Product, 2018 - 2030 (USD Million)
  • Table 22. U.K. Cloning and Mutagenesis Market, by Technology, 2018 - 2030 (USD Million)
  • Table 23. U.K. Cloning and Mutagenesis Market, End-user, 2018 - 2030 (USD Million)
  • Table 24. Germany Cloning and Mutagenesis Market, by Product, 2018 - 2030 (USD Million)
  • Table 25. Germany Cloning and Mutagenesis Market, by Technology, 2018 - 2030 (USD Million)
  • Table 26. Germany Cloning and Mutagenesis Market, End-user, 2018 - 2030 (USD Million)
  • Table 27. France Cloning and Mutagenesis Market, by Product, 2018 - 2030 (USD Million)
  • Table 28. France Cloning and Mutagenesis Market, by Technology, 2018 - 2030 (USD Million)
  • Table 29. France Cloning and Mutagenesis Market, End-user, 2018 - 2030 (USD Million)
  • Table 30. Italy Cloning and Mutagenesis Market, by Product, 2018 - 2030 (USD Million)
  • Table 31. Italy Cloning and Mutagenesis Market, by Technology, 2018 - 2030 (USD Million)
  • Table 32. Italy Cloning and Mutagenesis Market, End-user, 2018 - 2030 (USD Million)
  • Table 33. Spain Cloning and Mutagenesis Market, by Product, 2018 - 2030 (USD Million)
  • Table 34. Spain Cloning and Mutagenesis Market, by Technology, 2018 - 2030 (USD Million)
  • Table 35. Spain Cloning and Mutagenesis Market, End-user, 2018 - 2030 (USD Million)
  • Table 36. Denmark Cloning and Mutagenesis Market, by Product, 2018 - 2030 (USD Million)
  • Table 37. Denmark Cloning and Mutagenesis Market, by Technology, 2018 - 2030 (USD Million)
  • Table 38. Denmark Cloning and Mutagenesis Market, End-user, 2018 - 2030 (USD Million)
  • Table 39. Sweden Cloning and Mutagenesis Market, by Product, 2018 - 2030 (USD Million)
  • Table 40. Sweden Cloning and Mutagenesis Market, by Technology, 2018 - 2030 (USD Million)
  • Table 41. Sweden Cloning and Mutagenesis Market, End-user, 2018 - 2030 (USD Million)
  • Table 42. Norway Cloning and Mutagenesis Market, by Product, 2018 - 2030 (USD Million)
  • Table 43. Norway Cloning and Mutagenesis Market, by Technology, 2018 - 2030 (USD Million)
  • Table 44. Norway Cloning and Mutagenesis Market, End-user, 2018 - 2030 (USD Million)
  • Table 45. Asia Pacific Cloning and Mutagenesis Market, by Country, 2018 - 2030 (USD Million)
  • Table 46. Asia Pacific Cloning and Mutagenesis Market, by Product, 2018 - 2030 (USD Million)
  • Table 47. Asia Pacific Cloning and Mutagenesis Market, by Technology, 2018 - 2030 (USD Million)
  • Table 48. Asia Pacific Cloning and Mutagenesis Market, End-user, 2018 - 2030 (USD Million)
  • Table 49. China Cloning and Mutagenesis Market, by Product, 2018 - 2030 (USD Million)
  • Table 50. China Cloning and Mutagenesis Market, by Technology, 2018 - 2030 (USD Million)
  • Table 51. China Cloning and Mutagenesis Market, End-user, 2018 - 2030 (USD Million)
  • Table 52. India Cloning and Mutagenesis Market, by Product, 2018 - 2030 (USD Million)
  • Table 53. India Cloning and Mutagenesis Market, by Technology, 2018 - 2030 (USD Million)
  • Table 54. India Cloning and Mutagenesis Market, End-user, 2018 - 2030 (USD Million)
  • Table 55. Japan Cloning and Mutagenesis Market, by Product, 2018 - 2030 (USD Million)
  • Table 56. Japan Cloning and Mutagenesis Market, by Technology, 2018 - 2030 (USD Million)
  • Table 57. Japan Cloning and Mutagenesis Market, End-user, 2018 - 2030 (USD Million)
  • Table 58. Thailand Cloning and Mutagenesis Market, by Product, 2018 - 2030 (USD Million)
  • Table 59. Thailand Cloning and Mutagenesis Market, by Technology, 2018 - 2030 (USD Million)
  • Table 60. Thailand Cloning and Mutagenesis Market, End-user, 2018 - 2030 (USD Million)
  • Table 61. Australia Cloning and Mutagenesis Market, by Product, 2018 - 2030 (USD Million)
  • Table 62. Australia Cloning and Mutagenesis Market, by Technology, 2018 - 2030 (USD Million)
  • Table 63. Australia Cloning and Mutagenesis Market, End-user, 2018 - 2030 (USD Million)
  • Table 64. South Korea Cloning and Mutagenesis Market, by Product, 2018 - 2030 (USD Million)
  • Table 65. South Korea Cloning and Mutagenesis Market, by Technology, 2018 - 2030 (USD Million)
  • Table 66. South Korea Cloning and Mutagenesis Market, End-user, 2018 - 2030 (USD Million)
  • Table 67. Latin America Cloning and Mutagenesis Market, by Country, 2018 - 2030 (USD Million)
  • Table 68. Latin America Cloning and Mutagenesis Market, by Product, 2018 - 2030 (USD Million)
  • Table 69. Latin America Cloning and Mutagenesis Market, by Technology, 2018 - 2030 (USD Million)
  • Table 70. Latin America Cloning and Mutagenesis Market, End-user, 2018 - 2030 (USD Million)
  • Table 71. Brazil Cloning and Mutagenesis Market, by Product, 2018 - 2030 (USD Million)
  • Table 72. Brazil Cloning and Mutagenesis Market, by Technology, 2018 - 2030 (USD Million)
  • Table 73. Brazil Cloning and Mutagenesis Market, End-user, 2018 - 2030 (USD Million)
  • Table 74. Mexico Cloning and Mutagenesis Market, by Product, 2018 - 2030 (USD Million)
  • Table 75. Mexico Cloning and Mutagenesis Market, by Technology, 2018 - 2030 (USD Million)
  • Table 76. Mexico Cloning and Mutagenesis Market, End-user, 2018 - 2030 (USD Million)
  • Table 77. Argentina Cloning and Mutagenesis Market, by Product, 2018 - 2030 (USD Million)
  • Table 78. Argentina Cloning and Mutagenesis Market, by Technology, 2018 - 2030 (USD Million)
  • Table 79. Argentina Cloning and Mutagenesis Market, End-user, 2018 - 2030 (USD Million)
  • Table 80. Middle East & Africa Cloning and Mutagenesis Market, by Country, 2018 - 2030 (USD Million)
  • Table 81. Middle East & Africa Cloning and Mutagenesis Market, by Product, 2018 - 2030 (USD Million)
  • Table 82. Middle East & Africa Cloning and Mutagenesis Market, by Technology, 2018 - 2030 (USD Million)
  • Table 83. Middle East & Africa Cloning and Mutagenesis Market, End-user, 2018 - 2030 (USD Million)
  • Table 84. South Africa Cloning and Mutagenesis Market, by Product, 2018 - 2030 (USD Million)
  • Table 85. South Africa Cloning and Mutagenesis Market, by Technology, 2018 - 2030 (USD Million)
  • Table 86. South Africa Cloning and Mutagenesis Market, End-user, 2018 - 2030 (USD Million)
  • Table 87. Saudi Arabia Cloning and Mutagenesis Market, by Product, 2018 - 2030 (USD Million)
  • Table 88. Saudi Arabia Cloning and Mutagenesis Market, by Technology, 2018 - 2030 (USD Million)
  • Table 89. Saudi Arabia Cloning and Mutagenesis Market, End-user, 2018 - 2030 (USD Million)
  • Table 90. UAE Cloning and Mutagenesis Market, by Product, 2018 - 2030 (USD Million)
  • Table 91. UAE Cloning and Mutagenesis Market, by Technology, 2018 - 2030 (USD Million)
  • Table 92. UAE Cloning and Mutagenesis Market, End-user, 2018 - 2030 (USD Million)
  • Table 93. Kuwait Cloning and Mutagenesis Market, by Product, 2018 - 2030 (USD Million)
  • Table 94. Kuwait Cloning and Mutagenesis Market, by Technology, 2018 - 2030 (USD Million)
  • Table 95. Kuwait Cloning and Mutagenesis Market, End-user, 2018 - 2030 (USD Million) 

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information Procurement
  • Fig. 3 Primary Research Pattern
  • Fig. 4 Market Research Approaches
  • Fig. 5 Value Chain-Based Sizing & Forecasting
  • Fig. 6 Market Formulation & Validation
  • Fig. 7 Cloning and Mutagenesis, Market Segmentation
  • Fig. 8 Market Snapshot, 2022
  • Fig. 9 Market Trends & Outlook
  • Fig. 10 Market Driver Relevance Analysis (Current & Future Impact)
  • Fig. 11 Market Restraint Relevance Analysis (Current & Future Impact)
  • Fig. 12 Market Challenge Relevance Analysis (Current & Future Impact)
  • Fig. 13 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
  • Fig. 14 Porter's Five Forces Analysis
  • Fig. 15 Market Penetration Vs Growth Prospect Mapping, 2022
  • Fig. 16 Global Cloning and Mutagenesis Market: Product Movement Analysis
  • Fig. 17 Global Cloning and Mutagenesis Market, for Cloning Kits, 2018 - 2030 (USD Million)
  • Fig. 18 Global Cloning and Mutagenesis Market, for Mutagenesis Kits, 2018 - 2030 (USD Million)
  • Fig. 19 Global Cloning and Mutagenesis Market, for Others, 2018 - 2030 (USD Million)
  • Fig. 20 Global Cloning and Mutagenesis Market: Technology Movement Analysis
  • Fig. 21 Global Cloning and Mutagenesis Market, for Topo PCR Cloning, 2018 - 2030 (USD Million)
  • Fig. 22 Global Cloning and Mutagenesis Market, for Blunt End Cloning, 2018 - 2030 (USD Million)
  • Fig. 23 Global Cloning and Mutagenesis Market, for Seamless Cloning, 2018 - 2030 (USD Million)
  • Fig. 24 Global Cloning and Mutagenesis Market, for Site-Directed Mutagenesis, 2018 - 2030 (USD Million)
  • Fig. 25 Global Cloning and Mutagenesis Market, for Others, 2018 - 2030 (USD Million)
  • Fig. 26 Global Cloning and Mutagenesis Market: End-user Movement Analysis
  • Fig. 27 Global Cloning and Mutagenesis Market, for Biopharmaceutical & Pharmaceutical Companies, 2018 - 2030 (USD Million)
  • Fig. 28 Global Cloning and Mutagenesis Market, for CROs & CMOs, 2018 - 2030 (USD Million)
  • Fig. 29 Global Cloning and Mutagenesis Market, for Academic & Research Institutes, 2018 - 2030 (USD Million)
  • Fig. 30 Regional Marketplace: Key Takeaways
  • Fig. 31 Regional Outlook, 2022 & 2030
  • Fig. 32 Global Cloning and Mutagenesis Market: Regional Movement Analysis
  • Fig. 33 North America Cloning and Mutagenesis Market, 2018 - 2030 (USD Million)
  • Fig. 34 U.S. Cloning and Mutagenesis Market, 2018 - 2030 (USD Million)
  • Fig. 35 Canada Cloning and Mutagenesis Market, 2018 - 2030 (USD Million)
  • Fig. 36 Europe Cloning and Mutagenesis Market, 2018 - 2030 (USD Million)
  • Fig. 37 U.K. Cloning and Mutagenesis Market, 2018 - 2030 (USD Million)
  • Fig. 38 Germany Cloning and Mutagenesis Market, 2018 - 2030 (USD Million)
  • Fig. 39 France Cloning and Mutagenesis Market, 2018 - 2030 (USD Million)
  • Fig. 40 Italy Cloning and Mutagenesis Market, 2018 - 2030 (USD Million)
  • Fig. 41 Spain Cloning and Mutagenesis Market, 2018 - 2030 (USD Million)
  • Fig. 42 Denmark Cloning and Mutagenesis Market, 2018 - 2030 (USD Million)
  • Fig. 43 Sweden Cloning and Mutagenesis Market, 2018 - 2030 (USD Million)
  • Fig. 44 Norway Cloning and Mutagenesis Market, 2018 - 2030 (USD Million)
  • Fig. 45 Asia Pacific Cloning and Mutagenesis Market, 2018 - 2030 (USD Million)
  • Fig. 46 China Cloning and Mutagenesis Market, 2018 - 2030 (USD Million)
  • Fig. 47 India Cloning and Mutagenesis Market, 2018 - 2030 (USD Million)
  • Fig. 48 Japan Cloning and Mutagenesis Market, 2018 - 2030 (USD Million)
  • Fig. 49 South Korea Cloning and Mutagenesis Market, 2018 - 2030 (USD Million)
  • Fig. 50 Australia Cloning and Mutagenesis Market, 2018 - 2030 (USD Million)
  • Fig. 51 Thailand Cloning and Mutagenesis Market, 2018 - 2030 (USD Million)
  • Fig. 52 Latin America Cloning and Mutagenesis Market, 2018 - 2030 (USD Million)
  • Fig. 53 Brazil Cloning and Mutagenesis Market, 2018 - 2030 (USD Million)
  • Fig. 54 Mexico Cloning and Mutagenesis Market, 2018 - 2030 (USD Million)
  • Fig. 55 Argentina Cloning and Mutagenesis Market, 2018 - 2030 (USD Million)
  • Fig. 56 Middle East and Africa Cloning and Mutagenesis Market, 2018 - 2030 (USD Million)
  • Fig. 57 South Africa Cloning and Mutagenesis Market, 2018 - 2030 (USD Million)
  • Fig. 58 Saudi Arabia Cloning and Mutagenesis Market, 2018 - 2030 (USD Million)
  • Fig. 59 UAE Cloning and Mutagenesis Market, 2018 - 2030 (USD Million)
  • Fig. 60 Kuwait Cloning and Mutagenesis Market, 2018 - 2030 (USD Million)